Hae
Aineistot 11-20 / 22
Digoxin use and outcomes after myocardial infarction in patients with atrial fibrillation
Digoxin is used for rate control in atrial fibrillation (AF), but evidence for its efficacy and safety after myocardial infarction (MI) is scarce and mixed. We studied post-MI digoxin use effects on AF patient outcomes in ...
Patients with rheumatoid arthritis have impaired long-term outcomes after myocardial infarction: a nationwide case-control registry study
<p><strong>Objective: </strong>To investigate the long-term outcomes of patients with RA after myocardial infarction (MI).</p><p><strong>Methods: </strong>All-comer, real-life MI patients with RA (n = 1614, mean age 74 ...
Long-term outcomes of mechanical versus biological valve prosthesis in native mitral valve infective endocarditis
<p>Objectives. To study the long-term outcomes of mitral valve replacement with mechanical or biological valve prostheses in native mitral valve infective endocarditis patients. <br></p><p>Desing. We conducted a retrospective, nationwide, multicenter cohort study with patients aged ≤70 years who were treated with mitral valve replacement for native mitral valve infective endocarditis in Finland between 2004 and 2017. <br></p><p>Results. The endpoints were all-cause mortality, ischemic stroke, major bleeding, and mitral valve reoperations. The results were adjusted for baseline features (age, gender, comorbidities, history of drug abuse, concomitant surgeries, operational urgency, and surgical center). The median follow-up time was 6.1 years. The 12-year cumulative mortality rates were 36% for mechanical prostheses and 74% for biological prostheses (adj. HR 0.40; CI: 0.17-0.91; p = 0.03). At follow-up, the ischemic stroke had occurred in 19% of patients with mechanical prosthesis and 33% of those with a biological prosthesis (adj. p = 0.52). The major bleeding rates within the 12-year follow-up period were 30% for mechanical prosthesis and 13% for a biological prosthesis (adj. p = 0.29). The mitral valve reoperation rates were 13% for mechanical prosthesis and 12% for a biological prosthesis (adj. p = 0.50). Drug abuse history did not have a significant modifying impact on the results (interaction p = 0.51 for mortality and ≥0.13 for secondary outcomes). <br></p><p>Conclusion. The use of mechanical mitral valve prosthesis is associated with lower long-term mortality compared to the biological prosthesis in non-elder native mitral valve infective endocarditis patients. The routine choice of biological mitral valve prostheses for this patient group is not supported by the results.</p>...
Less revascularization in young women but impaired long-term outcomes in young men after myocardial infarction
<p><strong>Background: </strong>Female sex has previously been associated with poorer outcomes after myocardial infarction (MI), although evidence is scarce among young patients.</p><p><strong>Aim: </strong>We studied sex ...
Controlled register-based study of road traffic accidents in 12,651 Finnish cancer patients during 2013-2019
<p><strong>Background: </strong>Little controlled evidence exists on road traffic accident (RTA) risk among patients diagnosed with cancer, while clinicians are often requested to comment their ability to drive. The aim ...
Association of CHA2DS2-VASc Score with Long-Term Incidence of New-Onset Atrial Fibrillation and Ischemic Stroke after Myocardial Infarction
<p>The CHA<sub>2</sub>DS<sub>2</sub>-VASc score is a reliable tool used to estimate the risk of ischemic stroke (IS) in patients with atrial fibrillation (AF). Few tools exist for the prediction of new-onset AF (NOAF) after myocardial infarction (MI) and its relation to IS. We studied the usefulness of CHA<sub>2</sub>DS<sub>2</sub>-VASc in predicting NOAF and IS in a long-term follow-up after MI. Consecutive MI patients without baseline AF (n = 70,922; mean age: 68.2 years), discharged from 20 hospitals in Finland during 2005-2018, were retrospectively studied using national registries. The outcomes of interest after discharge were NOAF- and IS-assessed with competing risk analyses at one and ten years. The median follow-up was 4.2 years. The median baseline CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 3 (IQR 2-5). The likelihood of both NOAF and NOAF-related IS increased stepwise with this score at one and ten years (all p < 0.0001). The one-year-adjusted subdistribution hazard ratio (sHR) was 4.03 (CI 3.68-4.42) for NOAF in patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc scores ≥6 points. The cumulative incidence of IS was 15.2% in patients with NOAF vs. 6.2% in patients without AF at 10 years after MI (adj. sHR 2.12; CI 1.98-2.28; p < 0.0001). Coronary artery bypass surgery was associated with a higher NOAF incidence compared to percutaneous coronary intervention (adj. sHR 1.87; CI 1.65-2.13; p < 0.0001 one year after MI). The CHA<sub>2</sub>DS<sub>2</sub>-VASc score is a simple tool used to estimate the long-term risk of NOAF and IS after MI in patients without baseline AF. Coronary bypass surgery is associated with an increased NOAF incidence after MI.<br></p>...
Prognosis of patients with operated chronic subdural hematoma
Chronic subdural hematoma (cSDH), previously considered fairly benign and easy to treat, is now viewed a possible sign of incipient clinical decline. We investigated case-fatality, excess fatality and need for reoperations ...
Early statin use and cardiovascular outcomes after myocardial infarction: A population-based case-control study
<p>Background and aims<br>Statin therapy is a cornerstone of secondary prevention after myocardial infarction (MI). However, many patients do not use statins. We studied the association of not using statin early after MI ...
Childhood manifestations of 22q11.2 deletion syndrome: A Finnish nationwide register-based cohort study
<p>Aim<br>The aim of the study was to describe the clinical manifestations of 22q11.2 deletion syndrome patients in the Finnish paediatric population.</p><p>Methods<br>Nationwide registry data including all diagnoses and ...
Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction
<p>Background<br>To explore long-term cardiovascular prognosis after myocardial infarction (MI) among patients with type 1 diabetes.</p><p>Methods<br>Patients with type 1 diabetes surviving 90 days after MI (n = 1508; 60% ...